论文部分内容阅读
已知早孕人流前应用前列腺素(PG)对促进宫颈成熟有效,其作用机制是复杂的,除了对子宫收缩力和宫颈周围组织的影响外,还可促进内源性PG的产生。本文中作者报告了1983年5月至11月对100名早孕人流妇女使用二种前列腺素衍生物扩张宫颈的比较性研究。所有研究对象均为未产妇(82名为初孕妇,18名为经孕妇),闭经均少于12周,无使用PG的禁忌症(过敏、哮喘、心力衰竭、眼压增高、宫颈炎和阴道炎)。随机分为二组:A组50例,于人流术前3小时由病人自己将含PG0.1mg的Gemeprost阴道栓(PGE_1衍生物)放入阴道内。B组50例,于人流术前晚宫颈内放入含PG_(125)μg的PGF_(2α)胶0.5ml。二组对象年龄(平均22.2岁)、孕龄(平均9.5周)、过去史及用PG前宫颈
It is known that the application of prostaglandin (PG) to human cervix in early pregnancy is effective in promoting cervical ripening. Its mechanism of action is complex. In addition to its effect on uterine contractility and cervical tissue, PG can also promote the production of endogenous PG. In this paper, the authors report a comparative study of 100 prospective abortion women using two prostaglandin derivatives to expand the cervix between May and November 1983. All subjects were non-mothers (82 for first trimester and 18 for pregnant women) with amenorrhea less than 12 weeks and no contraindications to PG (allergies, asthma, heart failure, elevated intraocular pressure, cervicitis and vagina inflammation). Randomly divided into two groups: group A 50 cases, 3 hours before abortion by the patient himself will contain PG0.1mg Gemeprost vaginal suppository (PGE 1 derivatives) into the vagina. In Group B, 50 ml of PGF 2α glue containing 125 μg of PG were placed in the cervix before abortion. Two groups of subjects age (average 22.2 years old), gestational age (average 9.5 weeks), past history and with PG before the cervix